Results 231 to 240 of about 14,813,386 (261)

Manufacture of CAR-T cells in the body

Nature Biotechnology, 2017
Engineered T cells for cancer therapy are produced in the mouse bloodstream, avoiding the need to harvest T cells and manipulate them ex vivo.
openaire   +2 more sources

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Boll, Elie Azoulay   +2 more
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul Parikh
exaly  

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

Annals of Oncology, 2021
Karin Jordan, Carsten Müller-Tidow, Peter Dreger   +2 more
exaly  

An NK-like CAR T cell transition in CAR T cell dysfunction

Cell, 2021
Shelley Berger, Nils Wellhausen, Lifeng Tian   +2 more
exaly  

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

EBioMedicine, 2022
Diana Gumber, Leo Wang
exaly  

Long-term outcomes following CAR T cell therapy: what we know so far

Nature Reviews Clinical Oncology, 2023
James Kochenderfer
exaly  

Enhanced safety and efficacy of protease-regulated CAR-T cell receptors

Cell, 2022
Evan Weber, Kevin Parker, Crystal Mackall   +2 more
exaly  

IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy

Biomaterials, 2022
Lintao Cai, Baohong Li, Mingbin Zheng
exaly  

CAR T-cell therapy for B-cell lymphoma

Current Problems in Cancer, 2022
Samantha Jaglowski, Nathan Denlinger, David Bond   +2 more
exaly